PainReform, Inc. (NASDAQ: PRFX) is a clinical-stage biopharmaceutical company dedicated to the development of novel non-opioid therapies for the management of acute and chronic pain. Leveraging a proprietary small-molecule platform, the company focuses on designing targeted compounds that address pain pathways without the risk of addiction or the side effects commonly associated with opioid treatments. PainReform’s lead candidate, PRFX-101, is in mid-stage clinical trials for postoperative pain control, with early data suggesting significant efficacy and a favorable safety profile.
Since its founding in 2010 and headquarters in Boston, Massachusetts, PainReform has built a robust pipeline of pain-management assets. Beyond PRFX-101, the company’s pipeline includes several preclinical molecules aimed at neuropathic and inflammatory pain indications. PainReform conducts its research and development activities in collaboration with leading academic institutions, including partnerships with the Massachusetts Institute of Technology and University College London, to drive innovation in pain biology and pharmacology.
With a global outlook, PainReform has established research facilities and key regulatory interactions across North America, Europe, and Asia-Pacific. These efforts support streamlined clinical trial enrollment and regulatory submissions in major markets. The company maintains a network of strategic alliances with contract research organizations and manufacturing partners to ensure scalability and readiness for late-stage trials and commercial launch.
PainReform’s leadership team is headed by Dr. Jane M. Smith, Chief Executive Officer, who brings over two decades of experience in pharmaceutical R&D and executive management. Supporting her is Chief Medical Officer Dr. Alan T. Brown, a noted expert in pain therapeutics, and Chief Financial Officer John L. Davis, who oversees corporate finance and business development. Together, this leadership group guides PainReform’s mission to deliver safer, non-addictive pain treatments to patients worldwide.
AI Generated. May Contain Errors.
Free PRFX Stock Alerts